Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse 21:01:34 29/04/2024 BST After market 23:30:36
25.64 USD +0.94% Intraday chart for Pfizer, Inc. 25.65 +0.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
J&J, Bristol Myers lose challenges to US drug price negotiation program RE
Tesla Rally Boosts S&P 500, Nasdaq; This Week's Earnings, Fed Decision in Focus MT
Equity Markets Rise With Key Earnings, Fed Decision in Focus MT
US FDA grants full approval for Pfizer's cervical cancer drug RE
Equities Higher as Traders Await This Week's Key Earnings, Fed Decision MT
S&P 500 Companies' Latest Quarterly Results Mixed so Far, Oppenheimer Says MT
Equities Rise Intraday as Traders Await This Week's Key Earnings, Fed Decision MT
CAC40: limited downturn, despite the beginnings of a rate cut CF
CAC40: limited erosion, despite the beginnings of a rate cut CF
Labcorp Receives US FDA's Approval for Companion Diagnostic Device for Use With Pfizer's Hemophilia B Gene Therapy MT
Pfizer: presents new data at ASCO 2024 CF
Big tech saves the day, again Our Logo
CAC40: France's rating maintained = non-event CF
Earnings, Tech Outlooks Lift Wall Street Pre-Bell; Asia, Europe Up MT
CAC40: starts the week slightly up, crosses the 8100 mark CF
CAC 40: cautious rise ahead of a busy week CF
S&P 500 Posts First Weekly Gain Since March as Tech, Consumer Discretionary Lead Rise on Better-Than-Expected Earnings MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon MT
Pfizer Gets FDA Approval for Bleeding Disorder Treatment MT
Sector Update: Health Care Stocks Mixed Premarket Friday MT
Pfizer Receives FDA Approval for Rare Bleeding Disorder Treatment MT
Pfizer Receives FDA Approval for Rare Bleeding Disorder Treatment MT
Pfizer Receives FDA Approval for Rare Bleeding Disorder Treatment MT
Pfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia B DJ
US FDA approves Pfizer's gene therapy for rare bleeding disorder RE
Chart Pfizer, Inc.
More charts
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
25.4 USD
Average target price
31.62 USD
Spread / Average Target
+24.49%
Consensus
  1. Stock Market
  2. Equities
  3. PFE Stock
  4. News Pfizer, Inc.
  5. Pfizer Signs Agreement to License Acuitas Therapeutics' Lipid Nanoparticle Technology